Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27929442 | 0.98 | NOTUM (0.53) | NOTUMMAPK1ALDH1A1MAPTLMNA | |
| Ethane SCHEMBL8133601 | 0.96 | NOTUM (0.51) | NOTUMMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL3892764 | 0.89 | SCN9A (0.53) | NOTUMMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL1240259 | 0.88 | NOTUM (0.60) | NOTUMMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL1816455 | 0.82 | NOTUM (0.43) | NOTUMMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL2958737 | 0.81 | TDP1 (0.53) | ALDH1A1MAPTLMNATDP1KDM4E | |
| SCHEMBL10373626 | 0.79 | MAPT (0.77) | MAPK1ALDH1A1MAPTLMNAHTT | |
| SCHEMBL578424 | 0.79 | ALDH1A1 (0.50) | ALDH1A1MAPTAKR1C3USP2 | |
| SCHEMBL14242636 | 0.79 | L3MBTL3 (0.44) | MAPTTDP1USP2 | |
| SCHEMBL2158833 | 0.79 | NOTUM (0.54) | NOTUMMAPK1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| CN-111787916-B | Dihydroceramide desaturase inhibitors for treating diseases | 森陶鲁斯治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3737361-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | Centaurus Therapeutics (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2020-10-29 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1204665-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001009138-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| US-5889010-A | PSYCHOLOGICAL DISORDERS; UROGENITAL DISORDERS; COGNITION ACTIVATORS; NERVOUS SYSTEM DISORDERS; VISION DEFECTS; CONGESTIVE HEART FAILURE; DRUG ABRUSE; PARKINSON'S DISEASE;ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | PFIZER INC. (US) | 1999-03-30 | — | — | US | disclosed |
| US-4411904-A | Diphenylpropanamines, compositions thereof and use thereof | WARNER-LAMBERT COMPANY (US) | 1983-10-25 | — | — | US | disclosed |
| US-4364954-A | NEUROLEPTIC AGENT | WARNER-LAMBERT COMPANY (US) | 1982-12-21 | — | — | US | disclosed |
| US-4292321-A | 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof | WARNER-LAMBERT COMPANY (US) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | NOTUM 148/4885MAPK1 2698/4885ALDH1A1 1260/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NOTUM 3827/4885MAPK1 1392/4885ALDH1A1 355/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | NOTUM 131/4885MAPK1 3314/4885ALDH1A1 1500/4885 |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | NOTUM 148/4885MAPK1 2698/4885ALDH1A1 1260/4885 |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | NOTUM 148/4885MAPK1 2698/4885ALDH1A1 1260/4885 |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | NOTUM 148/4885MAPK1 2698/4885ALDH1A1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.